Sinovac Biotech, Ltd. SVA
Set alert
At close · Oct 28
Day range unavailable
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- —
- Prev close
- 6.47
- Mkt cap
- 642.44M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -53.92
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.47
- 200-d avg
- 6.47
- 1y target
- 3.52
News
3 weeks ago defenseworld.net
Sernova, Seraxis Aim for Type 1 Diabetes ‘Functional Cure’ With BetaNova Merger
Sernova (TSE: SVA) and Seraxis plan to combine to form BetaNova Biotherapeutics, a company focused on developing cell-based therapies intended to reduce or eliminate the need for external insulin in…
-
2 months ago benzinga.com
Sinovac Biotech H1 EPS $(0.84) Down From $0.06 YoY, Sales $147.079M Up From $130.270M YoY
Sinovac Biotech (NASDAQ:SVA) reported quarterly losses of $(0.84) per share. This is a 1500 percent decrease over earnings of $0.06 per share from the same period last year. The company reported…
2 months ago businesswire.com
SINOVAC Reports Unaudited First Half of 2026 Financial Results
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its unaudited financial…
3 months ago businesswire.com
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline…
-
4 months ago benzinga.com
Sinovac Biotech Regains Compliance With Nasdaq Listing Requirements
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated June 10, 2026…
4 months ago businesswire.com
SINOVAC Regained Compliance With the Nasdaq Global Market's Listing Requirements
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a notification…
4 months ago businesswire.com
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on…
-
5 months ago benzinga.com
Sinovac Biotech Requests Hearing Following New Delisting Determination Related To 2025 Annual Report Filing
Sinovac Biotech has today requested a hearing before the Panel. Such hearing request automatically stays the suspension of the Company's securities for a period of 22 calendar days from the date of…
5 months ago businesswire.com
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification…
-
5 months ago benzinga.com
Sinovac Biotech Has Extended The Deadline For Shareholders And Nominee Brokers To Submit Payment Instructions Relating Its Previously Declared Special Cash Dividend
The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company's common shares as of the close of business on May 23, 2025 ET. The…
5 months ago businesswire.com
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline…
-
5 months ago benzinga.com
Sinovac Biotech H1 Adj. EPS $0.06 Down From $1.18 YoY, Sales $130.270M Up From $128.711M YoY
Sinovac Biotech (NASDAQ:SVA) reported quarterly earnings of $0.06 per share. This is a 94.92 percent decrease over earnings of $1.18 per share from the same period last year. The company reported…
5 months ago businesswire.com
SINOVAC Reports Unaudited First Half of 2025 Financial Results
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results…
6 months ago businesswire.com
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 2024
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report…
9 months ago businesswire.com
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel…
10 months ago businesswire.com
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High…
10 months ago businesswire.com
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a…
-
10 months ago benzinga.com
Sinovac Biotech Announces Antigua High Court Makes Interim Order Giving Board Control Of The Company Until Trial Of Disputed 2025 Shareholder Meeting
Sinovac Biotech Ltd. (NASDAQ:SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has ordered that the directors Mr.…
10 months ago businesswire.com
Sinovac: Antigua Court Makes Interim Order Giving Board Control of the Company until the Trial of the Disputed 2025 Shareholder Meeting
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced that the Antigua High Court has…
-
11 months ago benzinga.com
Sinovac Biotech Receives Delisting Notice From Nasdaq; Co. Intends To Appeal Staff Determination
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that on November 12, 2025, it received a delisting…
11 months ago businesswire.com
SINOVAC Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that on November 12, 2025, it…
11 months ago prnewswire.com
Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
BOSTON , Nov. 11, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac…
1 year ago businesswire.com
SINOVAC Announces Appointment of Independent Auditor
BEIJING--(BUSINESS WIRE)--The Board of Directors and Management of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today…
1 year ago businesswire.com
SINOVAC Board Sets the Record Straight on July 8 Special Meeting of Shareholders
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”) today issued the following update to set the record straight regarding the Special…
1 year ago businesswire.com
Newly Elected Directors of Sinovac Hold the First Board Meeting
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (SINOVAC or the Company), a leading provider of biopharmaceutical products in China, today announced the new board of directors of the…
-
1 year ago benzinga.com
The Board of Directors of Sinovac Biotech Rejects The Recent Claims By Saif And The Imposter Former Board
The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading biopharmaceutical company in China, categorically rejects the recent deceptive and illegal claims…
1 year ago businesswire.com
SINOVAC Board of Directors Strongly Denounces Deceptive and Illegal Claims by SAIF and the Imposter Former Board
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, categorically rejects the recent…
1 year ago businesswire.com
SINOVAC Board of Directors Provides Update on Status of US$55.00 Special Cash Dividend Payment
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that…
-
1 year ago benzinga.com
Vivo Capital Announces U.S. Court Grants Injunction Against 1Globe And Li For Likely Disclosure Violations And Deception In Sinovac Case; Orders Mandates Both File Updated Disclosures Within 5 Days Of Order; Vivo Capital Urges Shareholders To Support SAIF Slate And Reject 1Globe Ahead Of July 8, 2025 Vote
Court Found That 1Globe and Li Likely Violated Disclosure Obligations; Mandates Both File Updated Disclosures Within 5 Days of OrderDecision Cites Prolonged Pattern of Corruption and Deception by…
-
1 year ago benzinga.com
SINOVAC Board Warns Shareholders As Advantech And Vivo Capital Legal Action Threatens $55.00 Special Dividend Distribution
Vivo Capital Challenges SINOVAC's Paying Agent on Distribution of the DividendOpposition Brief to be Filed Monday in Advance of Wednesday Hearing and Expected Friday Decision
-
1 year ago benzinga.com
SINOVAC Board Responds To Vivo Capital's Legal Threats, Defends $55/Share Special Dividend For Common Shareholders
In summary:We urge shareholders not to be misled by the Vivo group's attempts to relitigate an unappealable verdict by the Privy Council, rewrite history, and paint a fictitious picture of the last…
-
3 years ago benzinga.com
SINOVAC Updates on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its
-
3 years ago benzinga.com
Sinovac Biotech Board Unanimously Rejects an Unsolicited Partial Tender Offer from Alternative Liquidity Index To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced today that its Board of Directors (the "Board of
-
3 years ago benzinga.com
Alternative Liquidity Index Offers To Acquire up to 10M Shares of Sinovac Biotech for $0.03/Share in Cash
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
-
3 years ago benzinga.com
Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It
COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.
-
3 years ago benzinga.com
Reported Late Thursday, Sinovac Biotech's Varicella Vaccine Prequalified By WHO
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health
-
4 years ago benzinga.com
SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile
Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud
-
4 years ago benzinga.com
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
-
4 years ago benzinga.com
SINOVAC COVID-19 Vaccine Approved For Use In Children Above 6 months Of Age in Hong Kong
Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination
-
4 years ago benzinga.com
Which COVID-19 Vaccine(s) Significantly Prevented Deaths - Read To Find Out
Which COVID-19 Vaccine(s) Significantly Prevented Deaths - Read To Find Out
4 years ago benzinga.com
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited benefits for the company as the…
4 years ago benzinga.com
New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report
Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team
-
4 years ago benzinga.com
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ:
-
4 years ago benzinga.com
Sinovac's COVID-19 Vaccine With Pfizer Booster Less Effective Against Omicron: Reuters
China-based Sinovac Biotech Ltd's (NASDAQ: SVA) two-dose COVID-19 vaccine followed by a booster Pfizer Inc (NYSE: PFE) -BioNTech SE (NASDAQ:
-
4 years ago benzinga.com
Three Sinovac Doses Fail to Protect Against Omicron in Study
-Bloomberg https://www.bloomberg.com/news/articles/2021-12-23/three-sinovac-doses-fail-to-protect-against-omicron-study-shows?utm_source=google&utm_medium=bd&cmpId=google&sref=V7uxlNge
-
4 years ago benzinga.com
Sinovac Says Beijing Settled Litigation Of Its Business License And Seals BZ NOTE: Shares Of Sinovac Have Not Traded In Over A Year
SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, announced the Company's subsidiary SINOVAC Biotech Co., Ltd
-
4 years ago benzinga.com
Preliminary Results Show SINOVAC's COVID-19 Vaccine Demonstrates Good Safety Profile Among The Pediatric And Adolescent Population
SINOVAC Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced new preliminary data on its inactivated COVID-19 vaccine